Defense Advanced Research Projects AgencyTagged Content List

Threat Countermeasures

Actions that mitigate adversaries' capabilities

Showing 24 results for Countermeasures + Disease RSS
The Rapid Threat Assessment (RTA) program aims to provide critical information to speed production of medical countermeasures to protect U.S. forces against novel chemical and biological weapons. Such weapons have historically been mass-produced within a year of discovery. Development of countermeasures, however, currently takes far longer. Using current methods and technologies, researchers require decades of study to gain a cellular-level understanding of how new threat agents exert their effects.
Program Manager
Dr. Rohit Chitale joined DARPA as a program manager in 2019. He is an infectious disease epidemiologist with more than 20 years of experience helping national and international organizations establish and lead programs related to infectious disease prevention and eradication, with specific expertise in the design and implementation of disease surveillance systems and the development of new disease control tools.
Program Manager
Dr. Seth Cohen joined DARPA as a Program Manager in August 2019. He is interested in novel materials, new approaches to therapeutics/countermeasures, and biological and chemical technologies for stabilization/acquisition of scarce resources.
09/17/2020
DARPA is soliciting innovative proposals to develop (1) new therapeutics against Department of Defense (DoD)-priority bacterial threats that leverage host-driven protein degradation or deactivation pathways; and (2) a platform capability to rapidly develop, screen, and optimize therapeutics against emerging bacterial threats.